يعرض 1 - 5 نتائج من 5 نتيجة بحث عن 'Eduardo Gonzalez-Ochoa (16375918)', وقت الاستعلام: 0.01s تنقيح النتائج
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... حسب Stephanie Lheureux (16797697)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... حسب Stephanie Lheureux (16797697)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... حسب Stephanie Lheureux (16797697)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... حسب Stephanie Lheureux (16797697)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... حسب Stephanie Lheureux (16797697)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: